Sunvozertinib Earns FDA Accelerated Approval in EGFR Exon 20+ NSCLC

Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20insApproval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part B study, in which ZEGFROVY demonstrated statistically significant and clinically meaningful benefits to…

Sunvozertinib Granted FDA Accelerated Approval in EGFR Exon 20+ NSCLC

Sunvozertinib has received accelerated approval for use in advanced or metastatic non–small lung cancer harboring EGFR exon 20 insertion mutations.

Sunvozertinib Earns FDA Accelerated Approval in EGFR Exon 20+ NSCLC

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

FDA Accelerates Approval of Sunvozertinib for EGFR Exon 20+ NSCLC

FDA accelerates approval of sunvozertinib for advanced NSCLC with EGFR mutations, offering new hope for patients after chemotherapy.